Satyen Gada, MD
Allergy & Immunology · Springfield, VANPI 1780646497
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Sanofi accounts for 61.6% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $8,383, more than ten times the $278 reported in 2019.
Across 387 payments — averaging $50.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$12K
- AstraZeneca$2K
- GSK$764
- Regeneron Healthcare Solutions, Inc.$603
- Blueprint Medicines Corporation$560
- Grifols USA, LLC$491
- plus $3K from 22 others
What the payments were for
- Consulting fees$2,54113%
- Speaking & faculty fees$5,31227%
- Travel & lodging$1101%
- Food & beverage$11,36859%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 90 | $11,925 |
| AstraZeneca | 66 | $1,690 |
| GSK | 40 | $764 |
| Regeneron Healthcare Solutions, Inc. | 24 | $603 |
| Blueprint Medicines Corporation | 10 | $560 |
| Grifols USA, LLC | 24 | $491 |
| Novartis | 20 | $467 |
| Genentech USA, Inc. | 12 | $416 |
| Amgen | 21 | $385 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $241 |
| Optinose US, Inc. | 3 | $239 |
| ARS Pharmaceuticals Operations, Inc. | 12 | $212 |
| Kaleo, Inc. | 9 | $181 |
| Alk-abello, Inc | 3 | $164 |
| Galderma Laboratories, L.p. | 9 | $144 |
| Pfizer | 7 | $143 |
| Genentech, Inc. | 3 | $142 |
| Sanofi-aventis U.S. LLC | 1 | $112 |
| CSL Behring | 3 | $83 |
| Incyte Corporation | 4 | $81 |
| Biocryst US Sales Co., LLC | 3 | $73 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
| AbbVie | 3 | $63 |
| Lilly USA, LLC | 2 | $42 |
| Circassia Inc. | 1 | $20 |
| Organon | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,360 in reported general payments places this provider in the 80th percentile of 133 allergy & immunology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 17 | $654 |
| Montelukast Sodium | 15 | $188 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Springfield
- Oral AlpanSpringfield$88K
- Charles LaneLynchburg$1.4M
- Jacqueline Eghrari-SabetVienna$1M
- Eric KarlinWilliamsburg$522K
- Nicholas RiderRoanoke$227K
- Courtney BlairMc Lean$139K
- Andrew KimFredericksburg$104K
- Behnam DaghighLeesburg$99K
- Ananth ThyagarajanBurke$97K
- Larry BorishCharlottesville$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.